FGFR
Fibroblast growth factor receptor
FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.
All Product Categories
-
FGFR Inhibitors
(316)
View all products
-
FGFR Agonists
(4)
View all products
-
FGFR Antagonist
(1)
View all products
-
FGFR Activators
(5)
View all products
-
FGFR Modulators
(3)
View all products
-
FGFR Degraders
(11)
View all products
-
FGFR Control
(1)
View all products
-
FGFR Ligand
(1)
View all products
-
FGFR Proteins
(97)
View all products
-
FGFR-1 Proteins
(20)
View all products
-
FGFR-2 Proteins
(31)
View all products
-
FGFR-3 Proteins
(26)
View all products
-
FGFR-4 Proteins
(18)
View all products
-
FGFR Related Products (383)
Related Products (383)
-
Recombinant Proteins (97)
-
Antibodies (11)
-
KW-2449 (Standard)
0 ImagesCat. No.: HY-10339RCAS No.: 1000669-72-6
-
Dovitinib lactate (Standard)
0 ImagesSynonyms: CHIR-258 lactate (Standard); TKI-258 lactate (Standard)Dovitinib (lactate) (Standard) is the analytical standard of Dovitinib (lactate). This product is intended for research and analytical applications. Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
-
Lenvatinib mesylate (Standard)
0 ImagesSynonyms: E7080 mesylate (Standard)Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
-
H3B-6527 (Standard)
0 ImagesCat. No.: HY-100491RCAS No.: 1702259-66-2H3B-6527 (Standard) is the analytical standard of H3B-6527 (HY-100491). This product is intended for research and analytical applications. H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity.
-
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)
0 ImagesCat. No.: HY-P990252Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma.
-
SSR128129E free acid
0 ImagesCat. No.: HY-15599ACAS No.: 848463-13-8Synonyms: SSR free acidSSR128129E free acid is an orally available and allosteric FGFR inhibitor with an IC50 of 1.9 μM for FGFR1.
-
Pazopanib-d3 hydrochloride
0 ImagesCat. No.: HY-W705479CAS No.: 2469755-67-5Synonyms: GW786034-d3 hydrochloridePazopanib-d3 (hydrochloride) (GW786034-d3 (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
-
ENMD-2076 (Standard)
0 ImagesCat. No.: HY-10987ARCAS No.: 934353-76-1ENMD-2076 (Standard) is the analytical standard of ENMD-2076 (HY-10987A). This product is intended for research and analytical applications. ENMD-2076 is a multi-targeted Kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KdR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
-
SU 5402 (Standard)
0 ImagesCat. No.: HY-10407RCAS No.: 215543-92-3
-
Roblitinib (Standard)
0 ImagesSynonyms: FGF-401 (Standard)Roblitinib (Standard) is the analytical standard of Roblitinib (HY-101568). This product is intended for research and analytical applications. Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM. Roblitinib has antitumor activity.
-
AFG210
0 ImagesCat. No.: HY-18817CAS No.: 228400-22-4AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase.
-
Pemigatinib-d6
0 ImagesCat. No.: HY-W754878CAS No.: 2649492-49-7Synonyms: INCB054828-d6Pemigatinib-d6 (INCB054828-d6) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.
-
Ponatinib (Standard)
0 ImagesSynonyms: AP24534 (Standard)Ponatinib (Standard) is the analytical standard of Ponatinib. This product is intended for research and analytical applications. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
-
Ponatinib hydrochloride (Standard)
0 ImagesSynonyms: AP24534 hydrochloride (Standard)Ponatinib (hydrochloride) (Standard) is the analytical standard of Ponatinib (hydrochloride). This product is intended for research and analytical applications. Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
-
JK-P3 (Standard)
0 ImagesCat. No.: HY-108933RCAS No.: 942655-44-9JK-P3 (Standard) is the analytical standard of JK-P3 (HY-108933). This product is intended for research and analytical applications. JK-P3 is a potent and pan VEGFR2 inhibitor, with IC50s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor Kinase activity in vitro. JK-P3 has anti-angiogenic activity.
-
ENMD-2076 Tartrate (Standard)
0 ImagesCat. No.: HY-10987RCAS No.: 1453868-32-0ENMD-2076 Tartrate (Standard) is the analytical standard of ENMD-2076 (Tartrate) (HY-10987). This product is intended for research and analytical applications. ENMD-2076 Tartrate is a multi-targeted Kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KdR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
-
Fisogatinib (Standard)
0 ImagesSynonyms: BLU-554 (Standard)Fisogatinib (Standard) is the analytical standard of Fisogatinib (HY-100492). This product is intended for research and analytical applications. Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling.
-
Fexagratinib (Standard)
0 ImagesSynonyms: AZD4547 (Standard); ADSK091 (Standard)Fexagratinib (Standard) is the analytical standard of Fexagratinib. This product is intended for research and analytical applications. Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC50s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
-
Pazopanib (Standard)
0 ImagesSynonyms: GW786034 (Standard)Pazopanib (Standard) is the analytical standard of Pazopanib. This product is intended for research and analytical applications. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
-
Masitinib (Standard)
0 ImagesSynonyms: AB1010 (Standard)Masitinib (Standard) is the analytical standard of Masitinib. This product is intended for research and analytical applications. Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.
